stoxline Quote Chart Rank Option Currency Glossary
  
Kiniksa Pharmaceuticals, Ltd. (KNSA)
20.21  -0.325 (-1.58%)    04-17 16:00
Open: 20.53
High: 20.605
Volume: 528,927
  
Pre. Close: 20.535
Low: 20.15
Market Cap: 1,474(M)
Technical analysis
2025-04-17 4:50:19 PM
Short term     
Mid term     
Targets 6-month :  25.69 1-year :  28.39
Resists First :  21.99 Second :  24.3
Pivot price 20.75
Supports First :  18.25 Second :  15.18
MAs MA(5) :  20.39 MA(20) :  21.36
MA(100) :  20.64 MA(250) :  21.8
MACD MACD :  -0.5 Signal :  -0.3
%K %D K(14,3) :  46.5 D(3) :  45.3
RSI RSI(14): 44.5
52-week High :  28.14 Low :  16.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ KNSA ] has closed above bottom band by 38.4%. Bollinger Bands are 68% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 20.63 - 20.74 20.74 - 20.83
Low: 19.88 - 20.02 20.02 - 20.13
Close: 20 - 20.21 20.21 - 20.39
Company Description

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Headline News

Fri, 18 Apr 2025
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Outperform Rating from Wedbush - MarketBeat

Fri, 18 Apr 2025
Kiniksa Pharmaceuticals (KNSA) Projected to Post Earnings on Tuesday - MarketBeat

Thu, 17 Apr 2025
Arrowstreet Capital Limited Partnership Has $444,000 Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat

Thu, 17 Apr 2025
(KNSA) Investment Analysis and Advice - news.stocktradersdaily.com

Mon, 14 Apr 2025
Trexquant Investment LP Trims Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat

Tue, 08 Apr 2025
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 42 (M)
Shares Float 23 (M)
Held by Insiders 4 (%)
Held by Institutions 89.9 (%)
Shares Short 3,070 (K)
Shares Short P.Month 2,960 (K)
Stock Financials
EPS -0.61
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.05
Profit Margin -10.2 %
Operating Margin -15.8 %
Return on Assets (ttm) -5.2 %
Return on Equity (ttm) -9.9 %
Qtrly Rev. Growth 46.9 %
Gross Profit (p.s.) 5.57
Sales Per Share 10.07
EBITDA (p.s.) -1.05
Qtrly Earnings Growth 0 %
Operating Cash Flow 26 (M)
Levered Free Cash Flow 23 (M)
Stock Valuations
PE Ratio -33.69
PEG Ratio 0
Price to Book value 3.34
Price to Sales 2
Price to Cash Flow 33.04
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android